Meetings - The ASCO Post

The combination of the KRAS inhibitor sotorasib with afatinib, a pan-ErbB tyrosine kinase inhibitor, was feasible in treating patients with non–small cell lung cancer (NSCLC) and mutated KRAS whose di...

CNS Cancers

By The ASCO Post Staff / October 2021 / AACR-NCI-EORTC Virtual International Conference on Molecular Targets and Cancer Therapeutics

DM-CHOC-PEN May Improve Outcomes for Adolescents and Young Adults With Central Nervous System Tumors

In a phase II clinical trial, the drug 4-demethyl-4-cholesteryloxycarbonylpenclomedine (DM-CHOC-PEN) improved survival for some adolescent and young adult patients with cancers involving the central n...

Lung Cancer

By The ASCO Post Staff / October 2021 / AACR-NCI-EORTC Virtual International Conference on Molecular Targets and Cancer Therapeutics

Can Inhibition of the Aurora Kinase A Protein Help Overcome Resistance to KRAS Inhibition in Patients With Lung Cancer?

In preclinical models, combining an investigational Aurora kinase A (AURKA) inhibitor with a KRAS inhibitor or a WEE1 inhibitor showed efficacy against lung cancer cells with intrinsic or acquired res...

AACR-NCI-EORTC Virtual International Conference on Molecular Targets and Cancer Therapeutics

Second-Line Sotorasib Plus Afatinib for KRAS-Mutant NSCLC

DM-CHOC-PEN May Improve Outcomes for Adolescents and Young Adults With Central Nervous System Tumors

Can Inhibition of the Aurora Kinase A Protein Help Overcome Resistance to KRAS Inhibition in Patients With Lung Cancer?

Comparative Effectiveness of Acupuncture vs Massage for Relieving Pain in Patients With Advanced Cancer

Risk of Second Primary Breast Cancer in Young Breast Cancer Survivors

Adagrasib Plus Cetuximab in KRAS G12C–Mutated Colorectal Cancer

Improving Early Detection of Pancreatic Cancer in High-Risk Patients

Survival Rates in Patients With Cancer and Intellectual and Developmental Disabilities